Immune checkpoint inhibitors targeting the programmed cell death receptor (PD-1) and/or its ligand (PD-L1), approved for various malignancies, also show emerging potential in EMPD management, as evidenced by preclinical and clinical studies (12). This evidence concerns the gene CD274 and extramammary Paget disease.